Gilead's lenacapavir approval by the US Food and Drug Administration (FDA) marks a milestone in HIV prevention, but experts warn over its expense. Sophie Cousins reports.

On May 6, 2025, the Global Initiative For Asthma (GINA) published the 2025 update to their Global Strategy for Asthma ...

Level Meeting (HLM) on Noncommunicable Diseases and Mental Health (NCDs), which will be held on Sept 25, 2025 in New York, NY ...

One small city's bid to rescue its health finances has transformed the way health care is managed across China. Chris McCall ...

Non-valvular atrial fibrillation accounts for 13–26% of acute ischaemic strokes.1 Direct oral anticoagulants (DOACs) are ...

We welcome the Lancet Child & Adolescent Health Commission on the future of neonatology, calling for much needed attention to ...

PMI investment in supporting procurement and distribution of malaria control commodities would directly translate into ...

According to Loretta Ross and Rickie Solinger, reproductive justice “demands sexual autonomy and gender freedom for every ...

Considered a disease of middle-aged and older adults until the late 20th century, type 2 diabetes has risen markedly ...

Life, as philosopher Søren Kierkegaard put it, “must be understood backwards; but…it must be lived forwards”.1 Clinical ...

Vaccines have had a major impact on the control of infectious disease, most recently by helping to combat the COVID-19 ...

HIV response. Experts are suggesting a projected 24% decrease in HIV funding over the next year in the context of reductions ...